<DOC>
	<DOCNO>NCT00293280</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , lomustine , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well lomustine work treat patient stage III stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Lomustine Treating Patients With Stage III Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate response rate lomustine patient stage IIIB IV non-small cell lung cancer aberrant methylation MGMT gene . - Determine whether response rate patient significantly great historical control . Secondary - Collect preliminary data toxicity , disease stabilization , time disease progression , overall survival . Tertiary - Evaluate association clinical outcome immunohistochemical stain group patient complete partial loss MGMT gene . OUTLINE : This multicenter study . Patients receive oral lomustine day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month . PROJECTED ACCRUAL : A total 42 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell bronchogenic carcinoma , include follow histologic subtypes : Squamous cell Adenocarcinoma Adenosquamous Large cell anaplastic Bronchoalveolar Nonsmall cell carcinoma otherwise specify ( NOS ) Stage IIIB disease ( pleural effusion ) stage IV disease Stage IV patient brain metastasis eligible provide brain metastasis clinically stable treatment surgery and/or radiation therapy Tumors must test positive aberrant methylation MGMT gene methylationspecific polymerase chain reaction Bidimensionally measurable evaluable disease PATIENT CHARACTERISTICS : ECOG performance status 02 No active malignancy WBC ≥ 4,000/mm^3 OR absolute neutrophil count ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Total bilirubin normal AST &lt; 5 time upper limit normal Serum creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min No uncontrolled serious active infection Not pregnant nursing PRIOR CONCURRENT THERAPY : See Disease Characteristics More 3 week since prior chemotherapy No 2 prior chemotherapy regimens No prior therapy nitrosoureas Recovered prior radiation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
</DOC>